Amicus Therapeutics Executive and Leadership Team

Christopher Agee, the Chief Executive Officer at Amicus Therapeutics, directs the company's overall strategic vision and operational execution. Agee guides the organization's efforts in discovering, developing, and delivering novel medicines for rare metabolic diseases. This leadership involves fostering a culture of innovation and ensuring alignment across all departments to achieve critical development milestones. The Chief Executive Officer's purview extends to managing key stakeholder relationships, including investors and regulatory bodies, to advance the company's pipeline. By focusing on patient needs, Christopher Agee drives the company's mission to transform lives through high-quality therapeutic solutions. Agee's strategic direction ensures the efficient allocation of resources towards impactful research and development initiatives, solidifying the company's position in the biotechnology sector.

Tamariah Crowley, the Chairman & Chief Executive Officer at Amicus Therapeutics, provides overarching leadership and strategic direction for the global biotechnology firm. Crowley's role encompasses guiding the company's mission to discover, develop, and deliver innovative medicines for individuals with rare metabolic diseases. This involves setting the long-term vision, fostering a patient-centric culture, and ensuring robust governance structures are in place. The Chairman & Chief Executive Officer oversees critical strategic decisions, manages relationships with key partners and stakeholders, and champions the company's commitment to scientific excellence. By leading the executive team, Tamariah Crowley drives the advancement of the company's pipeline and its impact on patient communities worldwide. Crowley's leadership ensures Amicus Therapeutics remains at the forefront of rare disease therapeutics, focusing on delivering high-quality solutions.

Simon Harford, the Chief Financial Officer at Amicus Therapeutics, oversees all financial operations and strategic financial planning for the global biotechnology company. Harford manages capital allocation, financial reporting, investor relations, and treasury functions, ensuring the company's financial health and sustainability. This leadership role is critical in supporting the discovery, development, and delivery of novel medicines for rare metabolic diseases by securing necessary funding and managing budgets effectively. The Chief Financial Officer's responsibilities include driving financial performance, mitigating financial risks, and providing strategic financial insights to guide executive decision-making. By maintaining rigorous financial discipline, Simon Harford enables Amicus Therapeutics to pursue its ambitious pipeline and expand its impact on patient communities. Harford's financial acumen is essential for the company's long-term growth and mission fulfillment.

Steven Tay, the Chief Operating Officer at Amicus Therapeutics, directs the company's global operational activities and ensures efficient execution of its strategic objectives. Tay oversees manufacturing, supply chain management, and the scaling of operations to support the delivery of critical medicines for rare metabolic diseases. This leadership role involves optimizing production processes, maintaining high-quality standards, and ensuring the reliable availability of therapies to patients worldwide. The Chief Operating Officer's responsibilities also encompass driving operational excellence, managing cross-functional teams, and implementing best practices across all operational facets. By focusing on efficiency and quality, Steven Tay enables Amicus Therapeutics to effectively bring its innovative treatments from development to market. Tay's operational oversight is fundamental to the company's mission of transforming patient lives.

Sam Pierre-Louis, the Chief Information Officer at Amicus Therapeutics, architects and manages the company's technology infrastructure and digital strategy. Pierre-Louis oversees the implementation of advanced IT solutions that support research, development, and operational efficiency across the global organization. This includes ensuring data security, driving digital transformation initiatives, and leveraging technology to enhance collaboration among scientific and business teams. The Chief Information Officer's responsibilities extend to managing the company's information systems, supporting data analytics for drug discovery, and ensuring compliance with relevant technological regulations. By optimizing IT resources, Sam Pierre-Louis enables Amicus Therapeutics to accelerate its mission of delivering novel medicines for rare metabolic diseases. Pierre-Louis's strategic technology leadership is crucial for maintaining a competitive edge and supporting patient-focused innovation.

Ellen Rosenberg, the Chief Legal Officer at Amicus Therapeutics, provides comprehensive legal counsel and oversees all legal affairs for the global biotechnology organization. Rosenberg manages corporate governance, intellectual property strategy, regulatory compliance, and litigation matters, ensuring adherence to all applicable laws and regulations. This leadership role is vital in protecting the company's interests and facilitating the development and commercialization of novel medicines for rare metabolic diseases. The Chief Legal Officer's responsibilities include advising the board of directors and executive team on legal risks and opportunities, negotiating key agreements, and shaping legal strategies. By ensuring robust legal frameworks, Ellen Rosenberg supports Amicus Therapeutics' mission to deliver high-quality therapies and maintain its commitment to ethical business practices. Rosenberg's legal expertise safeguards the company's operations and strategic initiatives.